Photocure ASA

OSLO, Norway, April 5, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider will present a corporate overview and host 1-on-1 meetings with investors at the 23rd Annual Needham Healthcare Conference being held virtually April 8-11, 2024. Presentation Details: Date: April 11, 2024 Time: 10:15am ET (4:15pm CET) Webcast Link: About the Needham Healthcare Conference The 23rd Annual Needham Virtual Healthcare Conference will feature leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors. About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at , , For further information, please contact: Dan Schneider President and CEO Photocure ASA Email: [email protected] Erik Dahl CFO Photocure ASA Tel: +4745055000 Email: [email protected] David Moskowitz Vice President, Investor Relations Photocure ASA Tel: +1 202 280 0888 Email: [email protected] Media and IR enquiries: Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: [email protected] This information was brought to you by Cision The following files are available for download:

Newly elected members of Board of Directors consist of internationally merited business and clinical leaders Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement OSLO, Norway--(BUSINESS WIRE)-- Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the appointment of newly elected members of its Board of Directors (BOD) and the formation of a Scientific and Clinical Advisory Board under the leadership of founding scientists Roy Larsen and Øyvind Bruland, previous board members and leading experts in oncology and pharmaceutical development. “We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors. The extensive business and industry experience of these newly elected members will provide valuable guidance and leadership in furthering our mission during this pivotal time in Oncoinvent’s advancement,” said Anders Månsson, Chief Executive Officer of Oncoinvent. “We are also pleased to announce the formation of a Scientific and Clinical Advisory Board, consisting of our highly distinguished founders who are uniquely positioned to support Oncoinvent in our clinical programs. We believe that their breadth of resources and deep scientific knowledge, as well as their continued investment in the company, will provide critical insight as we prepare to move forward with the initiation of a Phase 2b clinical trial for Radspherin® in ovarian cancer, and seek to rapidly advance Radspherin® for colorectal cancer to Phase 3 testing following the completion of our Phase 2a study.” The newly appointed members of the Oncoinvent Board of Directors are as follows: Gillies O’Bryan-Tear, Chair, has over 30 years of experience in the pharmaceutical industry in clinical development, medical management and commercial roles. He has held senior leadership positions at a range of pharmaceutical and biotech companies in the US and Europe including Sanofi Aventis, Bristol-Myers Squibb, GSK, Takeda Pharmaceuticals, and Algeta ASA, and has been involved in multiple product approvals. Dr. O’Bryan-Tear has been an adviser to several US and European biotech companies and has held board positions at Fusion Pharmaceuticals and Clarity Pharmaceuticals. He holds a B.A. and M.B.B.S. from the University of Cambridge and an M.B.A from the Cranfield School of Management. Ingrid Teigland Akay is a founder and managing partner at Hadean Ventures. She also currently serves as a board member for Alex Therapeutics, Neuro Events Labs and Attgeno AB. Dr. Akay has supported start-up companies globally in multiple phases of development, from R&D to commercialization and has had previous medical experience in general medicine, surgery and psychiatry, with exposure to both the public and private sector. She holds a medical degree from Diminished Hochschule Hannover and an M.B.A. in Finance from London Business School. Kari Grønås is a managing director at K&K AS and holds board positions at Arxx Therapeutics, Ultimovacs and Spago Nanomedical AB. She has extensive experience in drug development and commercialization in the pharmaceuticals industry and has been involved in product regulatory approvals, including Xofigo and Hexvix. Ms. Grønås has also held previous leadership and management roles at Algeta ASA, PhotoCure and Nycomed Imaging/Amersham Health (Now GE Healthcare). She holds a M. Pharm. degree from the University of Oslo. Hilde Steineger, Ph.D., is the Chief Operating Officer and co-founder of NorthSea Therapeutics B.V. and Chief Executive Officer at Staten Biotechnology. She has held former board positions at Strongbridge BioPharma, Nordic Nanovector, PCI Biotech, Weifa AS, Inven2, Algeta ASA and Clavis Pharmas ASA. She has extensive experience in strategy and innovation, business development and investor relations, having held leadership positions at BASF and Pronova BioPharma. Dr. Steineger holds a Ph.D. in Medical Biochemistry and an M.Sc. in Biotechnology from the University of Oslo. Orlando Oliveira is Senior Vice President, Head of International at Mirati Therapeutics (acquired by BMS). He has nearly 25 years of experience in the pharmaceutical and biotech industry and has held previous leadership positions at Agios Pharmaceuticals (oncology business acquired by Servier in 2021), TESARO (acquired by GSK in 2019) and Cubist Pharmaceuticals (acquired by Merck/MSD in 2015). He has also held positions in medical, commercial, and general management during his 13 years at Amgen. Mr. Oliveira holds an M.Sc. in Pharmaceutical Sciences and a post-graduate degree in Drug and Pharmacy Law from Universidade de Coimbra. Anne Cecilie Alvik remains as an employee elected board member. In addition, Oncoinvent founding scientists Roy Larsen, Ph.D., and Øyvind Bruland, M.D., Ph.D., previously board members, will lead a newly established Scientific and Clinical Advisory Board. Both Dr. Larsen and Dr. Bruland have extensive experience the development of radiopharmaceuticals, as co-founders of several companies including Oncoinvent AS, Algeta AS, Nordic Nanovector AS, and ARTBIO. About Oncoinvent Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. Radspherin® is in two ongoing clinical studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent’s expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. View source version on businesswire.com: Contacts Anders Månsson, Chief Executive Officer mansson@oncoinvent.com Tore Kvam, Chief Financial Officer kvam@oncoinvent.com IR enquiries: Courtney Mogerley, Stern Investor Relations Courtney.Mogerley@sternir.com Source: Oncoinvent AS View this news release online at:

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week. This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC). The study author Sia Daneshmand, MD and the participants of the BLC with Cysview Study Group collected clinicopathologic information from adult patients undergoing transurethral resection of bladder tumor (TURBT) or biopsy who were enrolled in the multi-institutional BLC Cysview registry between April 2014 and February 2021. The primary outcome was detection of any malignant lesion on final pathology. Sensitivity, negative and positive predictive values for detection of malignant lesions were calculated for BLC, white light cystoscopy (WLC), and the combination of both modalities. Overall, 2379 separate samples were identified from 1292 patients, of whom, 1095 (85%) were White/Caucasian, 96 (7%) Black/African American, 51 (4%) Asian and 50 (4%) Hispanic. The sensitivity of WLC, BLC, and the combination of both for any malignant lesion was 88.7%, 95.8% and 99%, respectively, in the total cohort (P<0.001). BLC sensitivity vs. WLC was most significantly pronounced in the Asian population (96% vs 78%, P<0.001). In all races, the sensitivity of BLC was significantly higher than WLC for detection of CIS (P<0.001). Also, the addition of BLC to standard WLC increased the detection rate by 10% for any malignant lesion in the total cohort. This rate increased to 18% in Asian patients. Positive predictive value of BLC was also the highest in Asian population (94.4%). The authors conclude that regardless of race, BLC increased the detection of bladder cancer when combined with WLC. However, the difference was more pronounced in Asian patients: "Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC. These results could identify differences in groups that will lead to improved treatment of underserved minority populations. Further research is warranted to understand the underlying etiology of these observations which may ultimately alter interpretation of lesions detected by BLC," said Dr. Daneshmand. Read the full publication here: About the Blue Light Cystoscopy with Cysview Registry The U.S. Blue Light Cystoscopy with Cysview Registry (Clinical Trials: NCT02660645) is a large prospective, longitudinal, real-world evidence study in NMIBC* patients who have undergone TURBT** using Blue Light as an adjunct to white light cystoscopy. The Registry study was established by Photocure in 2014 and is projected to enroll 4400 patients. *NMIBC: Non-muscle invasive bladder cancer **TURBT: Transurethral resection of bladder tumor Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA About Bladder Cancer Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1 949 000 prevalent cases (5-year prevalence rate)1a, 614 000 new cases and more than 220 000 deaths in 2022.1b Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3 Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike. Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.4 1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: , accessed [February 2024]. 2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657 3 Sievert KD et al. World J Urol 2009;27:295–300 4 Bladder Cancer. American Cancer Society. About Hexvix®/Cysview® (hexaminolevulinate HCl) Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions. Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer to for further information on our commercial partners. About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at , , CONTACT: For further information, please contact: Dan Schneider President and CEO Photocure ASA Email: ds@photocure.com Erik Dahl CFO Photocure ASA Tel: +4745055000 Email: ed@photocure.com David Moskowitz Vice President, Investor Relations Photocure ASA Tel: +1 202 280 0888 Email: david.moskowitz@photocure.com Media and IR enquiries: Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: geir.bjorlo@corpcom.no This information was brought to you by Cision The following files are available for download: View original content: SOURCE Photocure Company Codes: Bloomberg:PHO@NO, ISIN:NO0010000045, Oslo:PHO, RICS:PHO.OL